Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to $77.1 million.

  • Syndax Pharmaceuticals' Accumulated Expenses rose 6023.15% to $77.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.1 million, marking a year-over-year increase of 6023.15%. This contributed to the annual value of $60.1 million for FY2024, which is 5078.28% up from last year.
  • As of Q3 2025, Syndax Pharmaceuticals' Accumulated Expenses stood at $77.1 million, which was up 6023.15% from $71.1 million recorded in Q2 2025.
  • In the past 5 years, Syndax Pharmaceuticals' Accumulated Expenses registered a high of $77.1 million during Q3 2025, and its lowest value of $11.4 million during Q1 2021.
  • Over the past 5 years, Syndax Pharmaceuticals' median Accumulated Expenses value was $24.3 million (recorded in 2022), while the average stood at $31.7 million.
  • In the last 5 years, Syndax Pharmaceuticals' Accumulated Expenses crashed by 4041.44% in 2021 and then surged by 16508.26% in 2025.
  • Syndax Pharmaceuticals' Accumulated Expenses (Quarter) stood at $14.5 million in 2021, then soared by 67.83% to $24.3 million in 2022, then surged by 64.18% to $39.9 million in 2023, then surged by 50.78% to $60.1 million in 2024, then increased by 28.3% to $77.1 million in 2025.
  • Its Accumulated Expenses was $77.1 million in Q3 2025, compared to $71.1 million in Q2 2025 and $56.0 million in Q1 2025.